D-14 Free Communication/Slide - Endocrinology: MAY 28, 2009 1:00 PM - 2:30 PM ROOM: 303
Effects Of Oxandrolone On Metabolic Syndrome Risk Factors: 758May 28 1:15 PM - 1:30 PM
PURPOSE: Assess the effect of a 12-week oral androgen treatment on metabolic syndrome (MetS) in healthy, older men.
METHODS: 27 men (age 71+6 years) were randomly selected to receive 20 mg/day oral oxandrolone (OXA, n = 17) or placebo (CTL, n = 10). Magnetic resonance imaging (MRI), blood assays, and clinical measures were used to evaluate the following MetS risk factors at baseline and after treatment: 1) waist circumference (WC) using cross-sectional MRI umbilical slices, 2) fasting serum triglycerides (TG), 3) serum high-density lipoprotein (HDL), 4) fasting plasma glucose (FG), and 5) systolic/diastolic blood pressure (SBP/DBP). Per AHA/NHLBI criteria, individuals with 3 or more risk factors were identified as positive for the MetS. Changes in MetS frequency were assessed using c2 proportion tests, and constituent risk factors evaluated with 2×2 (group × time) repeated measures ANOVA. Statistical significance was set at a = 0.05.
RESULTS: There were no significant changes in MetS frequency over the 12-week study period. Significant group × time interactions were found in selected risk factors, with the OXA group showing relative reductions in TG and HDL (Figure). Mean TG changes were -17±35 and +19±40 mg/dL for OXA and CTL groups, respectively (p = 0.02). Mean HDL changes were -19±8 and -3±5 mg/dL (p < 0.001). Other measures did not change significantly.
CONCLUSION: These data show that 12 weeks of oxandrolone administration modified selected MetS risk factors without altering overall MetS frequency. Treatment reduced both TG (↓ MetS risk) and HDL (↑ MetS risk). Future studies with expanded sample sizes and treatment regimens are needed to better understand these changes and their associated implications for long-term cardiovascular health.© 2009 American College of Sports Medicine